Anticoagulant Reversal/treatment options

**Dabigatran**
- 5.0g IV total dose [DOSEAGE ERROR CORRECTED] (given as two separate doses of 2.5g [DOSEAGE ERROR CORRECTED] 15 minutes apart)
  - Alternatives if idarucizumab is unavailable
    - Hemodialysis
    - Activated charcoal
      - 100g po/NG if ingestion time <2 hours
    - 4F-aPCC (FEIBA)
      - 50 units/kg IV; not to exceed 5000 units (single dose only)
    - Tranexamic acid
      - 25mg/kg IV
    - Desmopressin
      - 0.3mcg/kg SQ or IV; limit to 2 IV doses given
        - Increased risk of tachyphylaxis
    - FFP: Not recommended
    - rFVIIa: Not recommended

This Article Corrects: “Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016”

Steve Christos, DO, MS*
Robin Naples, MD†
*Presence Resurrection Medical Center, Department of Emergency Medicine, Chicago, Illinois
†Lewis Katz School of Medicine at Temple University, Department of Emergency Medicine, Philadelphia, Pennsylvania

Electronically published August 23, 2016
Full text available through open access at http://escholarship.org/uc/uciem_westjem
DOI: 10.5811/westjem.2016.8.32230
[West J Emerg Med.669–670.]
Apixaban
Activated charcoal
100g po/NG if ingestion time <6 hours

4F-PCC (KCenta / Octaplex)^
50 units/kg IV; not to exceed 5000 units (single dose only)

Tranexamic acid
25mg/kg IV

Desmopressin
0.3mcg/kg SQ or IV; limit to 2 IV doses given
Increased risk of tachyphylaxis

Andexanet alpha¥
400mg IV bolus at 30mg/min followed by continuous infusion at 4mg/min [DOSAGE ERROR CORRECTED] for 120 minutes

FFP: Not recommended
rFVIIa: Not recommended

Rivaroxaban
Activated charcoal
100g po/NG; if ingestion time <8 hours

4F-PCC (KCenta / Octaplex)^
50 units/kg IV; not to exceed 5000 units (single dose only)

Tranexamic acid
25mg/kg IV

Desmopressin
0.3mcg/kg SQ or IV; limit to 2 IV doses given
Increased risk of tachyphylaxis

Andexanet alpha¥
800mg IV bolus at 30mg/min followed by continuous infusion at 8mg/min [DOSAGE ERROR CORRECTED] for 120 minutes

FFP: Not recommended
rFVIIa: Not recommended

Figure 3. Reversal of direct oral anticoagulants (DOACs) in patients with significant bleeding.
IV, intravenous; FFP, fresh frozen plasma; rFVIIa, Recombinant human Factor VIIa; PCC, prothrombin complex concentrates; FEIBA, Factor Eight Inhibitor Bypassing Activity; NG, nasogastric
^Off label use.
^4F-PCC contains heparin and is contraindicated in patients with a history of heparin induced thrombocytopenia.
¥Not currently available on market. FDA trials ongoing. Dosing based on published Phase 3 trial.